Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RAD52 | P43351 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 6/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25820446 | 0.97 | PAOX (0.38) | PAOXTHRATHRBRAB9AKMT2A | |
| SCHEMBL8738807 | 0.97 | PAOX (0.38) | PAOXTHRATHRBRAB9AKMT2A | |
| SCHEMBL19829897 | 0.96 | PAOX (0.37) | PAOXTHRATHRBRAB9AKMT2A | |
| SCHEMBL8739618 | 0.95 | PAOX (0.38) | PAOXTHRATHRBRAB9AKMT2A | |
| SCHEMBL8739109 | 0.93 | THRA (0.40) | PAOXTHRATHRBACHE | |
| SCHEMBL26872388 | 0.93 | ACHE (0.36) | PAOXTHRATHRBKMT2AHRH3 | |
| SCHEMBL8738445 | 0.91 | PAOX (0.38) | PAOXTHRATHRBKMT2AHRH3 | |
| SCHEMBL10099918 | 0.91 | PAOX (0.35) | PAOXTHRATHRBKMT2AACHE | |
| SCHEMBL25822838 | 0.90 | PAOX (0.31) | PAOXTHRATHRBHRH3DRD3 | |
| SCHEMBL23762158 | 0.88 | PAOX (0.35) | PAOXKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697804-B2 | Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11697804-B2 | Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy | POLRMT, HDGF, PCNP | PAOX 1246/4885THRA 1193/4885THRB 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.